Articles
-
2 months ago |
hematologyadvisor.com | Stephan Cho
Chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel (ide-cel) continues to demonstrate a favorable benefit-risk profile compared with standard regimens (SRs) in triple-class-exposed (TCE) relapsed and refractory multiple myeloma (R/R MM), according to research published in Blood.
-
May 31, 2024 |
hematologyadvisor.com | Tori Rodriguez |Stephan Cho
As survival rates and treatment options continue to increase for patients with diffuse large B-cell lymphoma (DLBCL) in the Western world, those in low- and middle-income countries (LMICs) face ongoing challenges and disparities in diagnosis, treatment access, and outcomes.
-
Jul 13, 2023 |
clinicalpainadvisor.com | Stephan Cho
-
May 3, 2023 |
hematologyadvisor.com | Stephan Cho
-
Apr 12, 2023 |
clinicalpainadvisor.com | Stephan Cho
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →